InvestorsHub Logo
Followers 61
Posts 9563
Boards Moderated 0
Alias Born 03/29/2015

Re: ScrtKnight post# 36051

Monday, 06/08/2015 11:33:46 PM

Monday, June 08, 2015 11:33:46 PM

Post# of 702035
First, NWBO is able to patent large parts of their process but I am not sure everything is fully covered yet. This is why Dr. Bosch did not characterize the difference between Method A and Method B for the DCVax Direct trial. Ms. Powers used the infamous "secret sauce" language for the same reason, because NWBO wanted to make sure its intellectual property is covered before it gets too specific with what it is doing.

So yes, NWBO has a growing patent portfolio. Indeed, the company has alluded to the idea that their intellectual property with respect to manufacturing methods could generate licensing revenues from other firms. Others would be better at finding the exact quote but I certainly picked up on that point and I doubt I'm the only one who heard it.

Second, the UK facility is obviously a very bullish bet by NWBO executives.

If as Ms. Powers, has indicated, NWBO is to become a strong biotechnology company that will go the distance to commercialization on its own, this manufacturing capacity will be critical.

Having Cognate own the facility does not advance the goal of making NWBO self-sufficient let alone a big player in this market.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News